Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Pegylated Interferon Alfa-2a (Pegasys)
  Conference Data

  12th International Symposium on Viral Hepatitis and :Liver Disease
45th ICAAC
 XV International AIDS Conference
11th CROI
41st ICAAC



 		  
Home Page Main New/Newsworthy        
Last Update:  July 17, 2006
 Documents  identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader 5 .
12th International Symposium on Viral Hepatitis and
Liver Disease
  • A WEEK-IN-REVIEW FEATURED REPORT
    16 or 24 weeks of peginterferon alfa-2a (40kd) (pegasys®) plus ribavirin (rbv) (copegus®) in patients
    with hcv genotype 2 or 3 and bridging fibrosis or cirrhosis: results from a large, randomised multinational
    study (accelerate)
     Zeuzem S., Pappas S., Nyberg L., et al 
  • Antiviral therapy for hcv-associated cryoglobulinemia vasculitis: a long term follow-up.
    Cacoub P., Resche-Rigon M., Thibault V.
45th ICAAC
 
  • Baseline HCV Genotype 1 RNA Concentration: Relationships with Sustained Virologic
    Response to Peginterferon alfa-2a Plus Ribavirin and with Demographic Characteristics
         J. TICEHURST, J. RAKELA , H. BODENHEIMER, et al  (45 ICAAC)
  • Baseline HCV Genotype 1 RNA Concentration: Relationships with Sustained Virologic
    Response to Peginterferon alfa-2a Plus Ribavirin and with Demographic Characteristics
         J. TICEHURST, J. RAKELA , H. BODENHEIMER, et al  (45 ICAAC)
  • Treatment Exposure and Sustained Virologic Response (SVR) in Genotype 1 Patients Treated with
    Peginterferon alfa-2a (40KD) (PEG IFNα2a)+ Ribavirin (RBV) in APRICOT (AIDS PEGASYS Ribavirin
    International Co-Infection Trial)
         M. OPRAVIL, F. TORRIANI , J. SASADEUSZ,  et al  (45 ICAAC)
  • Predictability of Virologic Response at Week 4 and 12 of Peginterferon Alfa-2a (40KD) Plus Ribavirin
    (RBV) Therapy in HIV-HCV Co-Infection: AIDS PEGASYS Ribavirin International Co-Infection Trial
    (APRICOT)
         F.J. TORRIANI, M. RODRIGUEZ-TORRES , E. LISSEN , et al  (45 ICAAC)
  • Impact of Growth Factors (GF) on Treatment Outcomes in Patients with HIV-HCV Co-Infection in
    the AIDS PEGASYS Ribavirin (RBV) International Co-Infection Trial (APRICOT)
         M. SULKOWSKI, N. BRÄU , F. J. TORRIANI , et al  (45 ICAAC)
  • Comparison of Pegylated Interferons Alfa-2a and Alfa-2b in HCV/HIV-1 Co-Infected Patients
         J. SLIM, J.P. FALLON, N. SCANGARELLO, S.M. SMITH;  (45 ICAAC)